Featured Research

from universities, journals, and other organizations

Targeting T cells effectively blocks multiple sclerosis in mice

Date:
February 25, 2011
Source:
Wayne State University - Office of the Vice President for Research
Summary:
In an effort to develop therapeutic remedies for multiple sclerosis, scientists debate two possible interventional approaches -- but they're on opposite sides of the spectrum. Researchers however, think they have now reached a definitive conclusion as to which approach is correct, putting an end to a long-disputed issue. They found that targeting white blood cells of the immune system known as T cells is the effective approach to block the disease in an animal model of MS.

In an effort to develop therapeutic remedies for multiple sclerosis, scientists debate two possible interventional approaches -- but they're on opposite sides of the spectrum. Researchers at Wayne State University's School of Medicine, however, have reached a definitive conclusion as to which approach is correct, putting an end to a long-disputed issue.

Harley Tse, Ph.D., associate professor of immunology and microbiology at WSU's School of Medicine and resident of West Bloomfield, Mich., whose study was published in the January 2011 edition of the Journal of Neuroimmunology, found that targeting white blood cells of the immune system known as T cells is the effective approach to block the disease in an animal model of MS, experimental autoimmune encephalomyelitis.

Normally, T cells are programmed to attack foreign substances in the body. However, sometimes these T cells attack an essential component of the central nervous system, the protective layer of nerve cells known as the myelin sheath. This causes the symptoms associated with MS, which include tremors, fatigue, memory loss and other problems.

The debate was centered on treatment of the most common form of the disease, the remitting-relapse form, in which attack episodes alternate with periods of remission. Roughly 85 percent of the 2.5 million sufferers of MS worldwide exhibit the remitting-relapse pattern. "Scientists have been trying to understand how and why the relapse cycles occur and to design therapy to delay disease relapses and hence prolong the remission period," said Tse.

Scientists came up with two conflicting conjectures. Some found that the T cells involved in each relapse were different and were directed against different myelin proteins. As such, these T cells are not suitable targets for therapy. Others, however, could not find support for this in their studies. "It was important to resolve this issue because the two models suggested totally different therapeutic approaches," Tse said.

Studying the possibilities, Tse constructed a special mouse strain to tag the disease-causing T cells and observed that when these marked T cells were eliminated after a relapse, subsequent relapses did not occur.

"Elimination of marked donor T cells could be done after development of the second or the third relapse episodes and each time, no further relapses occurred," said Tse. "This work is significant because for the first time we are able to definitively establish a cause-and-effect relationship linking the marked T cells to the development of relapses and show unambiguously that it was the same T cells that mediated relapsing cycles. "

"Targeting such disease-causing T cells in MS is definitely a valid therapeutic approach that should be pursued," Tse added.

Other WSU researchers involved in the study were Jinzhu Li, M.D., Ph.D., Xiaoqing Zhao, M.D., Ph.D, Hui-Wen Hao, M.D., Ph.D. and Michael K. Shaw, Ph.D. Tse's study was supported in part by grants from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health and the National Multiple Sclerosis Society.


Story Source:

The above story is based on materials provided by Wayne State University - Office of the Vice President for Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jinzhu Li, Xiaoqing Zhao, Hui-Wen Hao, Michael K. Shaw, Harley Y. Tse. T cells that trigger acute experimental autoimmune encephalomyelitis also mediate subsequent disease relapses and predominantly produce IL-17. Journal of Neuroimmunology, 2011; 230 (1-2): 26 DOI: 10.1016/j.jneuroim.2010.08.007

Cite This Page:

Wayne State University - Office of the Vice President for Research. "Targeting T cells effectively blocks multiple sclerosis in mice." ScienceDaily. ScienceDaily, 25 February 2011. <www.sciencedaily.com/releases/2011/02/110223163607.htm>.
Wayne State University - Office of the Vice President for Research. (2011, February 25). Targeting T cells effectively blocks multiple sclerosis in mice. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2011/02/110223163607.htm
Wayne State University - Office of the Vice President for Research. "Targeting T cells effectively blocks multiple sclerosis in mice." ScienceDaily. www.sciencedaily.com/releases/2011/02/110223163607.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins